Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
BURLINGTON, Mass., June 23, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been recognized as one of the The Boston Business Journal’s “Best Places to Work.” Flexion ranked 5th in the medium business category (100 to 249 employees) and was presented with the award at a ceremony held last night at Symphony Hall in Boston.
The Best Places to Work program honors leading employers from the greater Boston area for going “above and beyond” to create an exceptional work environment for their employees. Companies must have a physical office in Massachusetts and are judged based on the results of an employee survey evaluating: communication and resources, individual needs, manager effectiveness, personal engagement, team dynamics and trust in leadership.
Flexion’s mission is to advance transformative therapies that have the potential to make a meaningful difference for patients confronting musculoskeletal conditions. The company is distinguished by five core values that define its culture – focus, ingenuity, tenacity, transparency and fun. These values serve as the pillars upon which co-founders, Michael Clayman, M.D., President and Chief Executive Officer and Neil Bodick, M.D., Ph.D., Chief Scientific Officer, established and grew Flexion. In 2016, the company expanded from 50 to 100 employees, and it plans to reach approximately 250 people by the end of 2017.
“We have a remarkably talented team of people with deep expertise and unrivaled passion,” said Dr. Clayman. “From the outset, Neil and I appreciated the importance of attracting outstanding professionals who truly share our vision and want to be a part of a high-performing, respectful and collaborative organization. We have worked hard to create and foster a culture that values great ideas and gives everyone a voice. We are honored by this recognition and extend our sincere gratitude to our colleagues who live and breathe our core values and make Flexion such a fun place to work.”
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
